Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 30 days matching "bile-duct-cancer"

Clinical trialUNITERAREMay 8

New Recruiting Trial: A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)

Researchers are testing whether smartwatches can help track hot flashes and other heat-related symptoms in men with prostate cancer who are receiving hormone therapy. The study will measure body temperature, heart rate, and skin changes using wearable technology to see if this is a practical way to monitor these side effects.

WHY IT MATTERSThis trial offers prostate cancer patients on androgen deprivation therapy a potential new way to objectively track vasomotor symptoms they experience, which could lead to better symptom management and treatment decisions.
👁 Watch this spaceprostate cancer
🔴 BreakingDrug approvalRSSMay 8

FDA Grants Seventh Approval under the National Priority Voucher Pilot Program

The FDA approved a new drug called Bizengri that treats a very rare and aggressive bile duct cancer called NRG1 fusion-positive cholangiocarcinoma. This approval is special because it's the seventh drug to receive fast-track approval through the FDA's National Priority Voucher Pilot Program, which helps speed up treatments for the rarest diseases. This cancer forms in the tubes that carry bile from the liver, and this new treatment targets a specific genetic change found in some patients with this disease.

WHY IT MATTERSPatients with NRG1 fusion-positive cholangiocarcinoma now have access to the first FDA-approved targeted treatment specifically designed for their genetic subtype of this ultra-rare cancer.
💬 Ask your doctorNRG1 fusion-positive cholangiocarcinoma
Clinical trialUNITERAREMay 2

New Recruiting Trial: Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)

Researchers at the University of Oklahoma are looking for Native American people with prostate cancer to join a study starting in May 2026. The study will examine the genetic makeup of prostate cancer in Native American communities to better understand why this disease affects them differently than other groups. This research could help doctors develop better treatments tailored to Native American patients.

WHY IT MATTERSThis trial specifically focuses on Native American prostate cancer patients, a population historically underrepresented in cancer research, which means findings could lead to more personalized and effective treatment approaches for this community.
👁 Watch this spaceprostate cancer

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases